# A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

> **NCT00988052** · PHASE3 · TERMINATED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 839 (actual)

## Conditions studied

- Relapsing Multiple Sclerosis

## Interventions

- **DRUG:** Laquinimod

## Key facts

- **NCT ID:** NCT00988052
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11-10
- **Primary completion:** 2017-07-01
- **Final completion:** 2017-07-01
- **Target enrollment:** 839 (ACTUAL)
- **Why stopped:** Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the study drug in the relevant dose.
- **Last updated:** 2021-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00988052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00988052, "A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00988052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*